ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $62.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.